Last reviewed · How we verify

Roactemra biosimilars

Complete Roactemra (tocilizumab) biosimilar landscape: 10 approved biosimilars, 0 filed, 6 in Phase 3. Sponsor, approval status, first approval date, and patent timeline for the originator.

10 approved 0 filed 6 Phase 3 All key patents expired

About Roactemra

Roactemra (tocilizumab) — originally marketed by Roche. Class: Interleukin-6 Receptor Antagonist [EPC]. Target: Interleukin-6 receptor. Area: Oncology. First approved 2010-01-01.

Approved biosimilars (10)

BiosimilarSponsorPhaseFirst approvalCountry
TOCILIZUMAB marketed 2005-01-01
AVTOZMA CELLTRION INC marketed
Tocilizumab, Abatacept Assistance Publique - Hôpitaux de Paris marketed
TYENNE FRESENIUS KABI USA marketed
Tocilizumab Prefilled Syringe Syneos Health marketed
tocilizumab or sarilumab Pfizer marketed
TOFIDENCE BIOGEN MA marketed
tocilizumab [RoActemra/Actemra] Hoffmann-La Roche marketed
Tocilizumab(400mg) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University marketed
Tocilizumab plus methotrexate SURPRISE Study Group marketed

Filed biosimilars under regulatory review (0)

No biosimilars currently under regulatory review.

Phase 3 biosimilars (6)

BiosimilarSponsorPhaseFirst approvalCountry
CT-P47 AI (tocilizumab) Celltrion phase 3
Tocilizumab Injection Abderrahmane Mami Hospital phase 3
tocilizumab IV Hoffmann-La Roche phase 3
Tocilizumab treatment Centre Hospitalier Universitaire Dijon phase 3
tocilizumab SC Hoffmann-La Roche phase 3
Tocilizumab Prefilled Syringe [Actemra] Medical University of Vienna phase 3

Originator patent timeline

Active patents (0)

No active patents tracked.

Expired patents (0)

No expired patents tracked.

Subscribe to biosimilar updates

Every regulatory action on Roactemra or any of its biosimilars:

Related